BioSpace News Archive

Today, the U.S. Food and Drug Administration announced the final decision to withdraw approval of Makena—a drug that had been approved under the accelerated approval pathway.

Alfred K. Cheung, MD, a clinical nephrologist and researcher, will receive the National Kidney Foundation’s David M. Hume Memorial Award for his high ideals of scholarship and humanism in an outstanding manner in the field of academic nephrology.

Rhythm Pharmaceuticals, Inc. announced that on April 4, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 21,870 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 14,580 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 7,290 shares of its common stock.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 7 new employees with a grant date of April 3, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023.

Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023.

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2023, after the close of the stock market on Wednesday, April 26, 2023.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions,

Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”) and NutraLife Biosciences (OTC Markets: NLBS) (“NLBS”), a highly-respected manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis, today announced they have renewed collaborative efforts initiated four years ago.